Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy

Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with... ORIGINAL ARTICLE Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy Theodoros Tsakiridis, MD, PhD,*† Jean-Claude Cutz, MD,‡§ Gurmit Singh, PhD,† Hal Hirte, MD,*† Gordon Okawara, MD,*† Tom Corbett, MD,*† Ranjan Sur, MD, PhD,*† Wenjie Cai, BSc,† Tim Whelan, MD,*† and James R. Wright, MD*† Key Words: NSCLC, Radiotherapy, Epidermal growth factor re- Introduction: The epidermal growth factor receptor (EGFR) and its ceptor, Prognostic marker, Extracellular signal regulated kinase. downstream effector kinases are thought to have important roles in (J Thorac Oncol. 2008;3: 716–722) lung cancer cell proliferation and response to treatment. Methods: In a prospective cohort of patients with locally advanced non-small cell lung cancer (NSCLC) undergoing high-dose radio- on-small cell lung cancers (NSCLC) account for 70 to therapy with or without chemotherapy, we examined by immuno- N80% of all bronchogenic carcinomas, and the majority histochemistry (IHC) the tumor levels of EGFR and phosphorylated/ of patients present with locally advanced (LA), unresectable activated-EGFR (P-EGFR), P-Erk, P-Akt, P-Stat3, and the cell cycle disease. LA-NSCLC has a poor prognosis with 2-year sur- marker Ki67. We examined the relationships among marker expres- vival of 20 to 30% and only http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy

Wright, James R.
Journal of Thoracic Oncology , Volume 3 (7) – Jul 1, 2008
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/association-of-phosphorylated-epidermal-growth-factor-receptor-with-Kg0P8uYwBq

References (22)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31817c6094
pmid
18594316
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy Theodoros Tsakiridis, MD, PhD,*† Jean-Claude Cutz, MD,‡§ Gurmit Singh, PhD,† Hal Hirte, MD,*† Gordon Okawara, MD,*† Tom Corbett, MD,*† Ranjan Sur, MD, PhD,*† Wenjie Cai, BSc,† Tim Whelan, MD,*† and James R. Wright, MD*† Key Words: NSCLC, Radiotherapy, Epidermal growth factor re- Introduction: The epidermal growth factor receptor (EGFR) and its ceptor, Prognostic marker, Extracellular signal regulated kinase. downstream effector kinases are thought to have important roles in (J Thorac Oncol. 2008;3: 716–722) lung cancer cell proliferation and response to treatment. Methods: In a prospective cohort of patients with locally advanced non-small cell lung cancer (NSCLC) undergoing high-dose radio- on-small cell lung cancers (NSCLC) account for 70 to therapy with or without chemotherapy, we examined by immuno- N80% of all bronchogenic carcinomas, and the majority histochemistry (IHC) the tumor levels of EGFR and phosphorylated/ of patients present with locally advanced (LA), unresectable activated-EGFR (P-EGFR), P-Erk, P-Akt, P-Stat3, and the cell cycle disease. LA-NSCLC has a poor prognosis with 2-year sur- marker Ki67. We examined the relationships among marker expres- vival of 20 to 30% and only

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jul 1, 2008

There are no references for this article.